Boston, MA – April 29, 2026 – Panalgo, a Norstella company, and Navidence today announced a strategic partnership that embeds Navidence’s validated patient definitions directly into Panalgo’s Instant Health Data (IHD) platform. The collaboration addresses one of the most persistent challenges in real-world data (RWD) analytics, defining diseases and therapies consistently and accurately, by making clinically reviewed phenotype definitions natively available within the analytics workflow.
Across the industry, RWD analyses are often slowed by inconsistent definitions, manual code identification, and limited clinical validation. Analysts can spend 8–12 weeks per project manually identifying and verifying the right codes (ICD, SNOMED, NDC, and more), a process that introduces variability and erodes confidence in results. The Panalgo–Navidence partnership eliminates that friction, by delivering a seamless, end-to-end, standardized approach to defining and analyzing patient populations.
With this integration, IHD users gain access to Navidence’s library of clinically reviewed phenotype definitions by therapeutic areas and indications, covering diseases, therapies, and associated code sets directly within their workflows. These definitions can be searched, selected, and applied without leaving the platform, enabling faster, more precise, and more reproducible analyses.
“Real-world evidence is only as good as the underlying definitions allow. This partnership brings clinical rigor directly into the analytics environment,” said Aaron Kamauu, CEO and co-founder of Navidence. “By embedding our definitions into IHD, we enable researchers to define once and trust everywhere: reducing variability, increasing transparency, and improving the quality of real-world evidence.”
The integration provides a single platform for users to design studies, access standardized data definitions, and move rapidly from study design to query and analysis. Navidence code lists are now fully accessible within IHD, allowing users to view underlying codes, metadata, and source documentation for complete transparency and auditability.
Navidence code lists function like any other IHD code list, enabling the creation of patient cohorts, dashboards, and analyses using the full IHD toolkit. They can also be used in conjunction with Panalgo’s Ella AI to accelerate cohort building and real-world evidence generation even further.
“This partnership is about removing friction from one of the most time-consuming and risk-prone parts of RWD analytics,” said Kevin D’Ambrosia, Chief Revenue Officer, HEOR, RWD and RWE, Norstella. “By integrating clinically validated definitions directly into IHD, we’re helping teams move faster from question to insight while improving consistency, transparency, and trust in the results.”
The result is a unified, intelligent analytics experience where validated definitions are built in, not bolted on, directly facilitating the generation of high-quality evidence.
About Navidence
Navidence helps healthcare and life sciences organizations design and assess the use of real-world data in clinical research studies and clinical trials. Through its platform and Computable Operational Definitions (CODefs), Navidence enables consistent, transparent, and reproducible analysis of complex real-world data, supporting smarter, more efficient research and better patient outcomes. To learn more, visit www.navidence.com and follow Navidence on LinkedIn.
About Panalgo
Panalgo, a Norstella company, is your partner on the healthcare data analytics journey. Its Instant Health Data (IHD) platform eliminates complex programming, making data analysis faster and decision-making more impactful. Through partnerships across the industry, Panalgo streamlines access to real-world data, offering a complete solution from data to insights. Whether it’s industry-leading software, access to data, expert analytic services, or a combination of all three, Panalgo supports organizations at every stage of their analytics journey. Learn more at www.panalgo.com and follow Panalgo on LinkedIn.